Adaptive Biotechnologies Corporation
ADPT
주식 순위
#4180
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
주가
$23.98
마지막 동기화: 2026-10-19
시가총액
$3.83B
변동 (1일)
-0.17%
변동 (1년)
34.49%
국가
US
거래 Adaptive Biotechnologies Corporation (ADPT)
카테고리
Healthcare
Adaptive Biotechnologies Corporation (ADPT)의 발행 주식 수
June 2026 기준 발행 주식 수: 157.70M
Adaptive Biotechnologies Corporation의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 157.70M입니다. December 2024 말 기준 회사는 147.10M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Adaptive Biotechnologies Corporation (ADPT)의 발행 주식 수 기록 (2017 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 157.70M | 3.94% |
| 2025 | 151.72M | 3.14% |
| 2024 | 147.10M | 1.88% |
| 2023 | 144.38M | 1.31% |
| 2022 | 142.52M | 1.54% |
| 2021 | 140.35M | 6.96% |
| 2020 | 131.22M | 5.53% |
| 2019 | 124.34M | 17.93% |
| 2018 | 105.43M | 0.00% |
| 2017 | 105.43M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 253.90M | 61.00% |
US
|
|
| 396.00M | 151.11% |
US
|
|
| 478.91M | 203.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -60.57% |
NL
|
